Contrasting Grifols SA, Barcelona (GRFS) and Mateon Therapeutics (MATN)

Grifols SA, Barcelona (NASDAQ: GRFS) and Mateon Therapeutics (OTCMKTS:MATN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Earnings and Valuation

This table compares Grifols SA, Barcelona and Mateon Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Grifols SA, Barcelona $4.48 billion 3.34 $603.60 million $0.93 23.55
Mateon Therapeutics N/A N/A -$13.65 million ($0.56) -0.41

Grifols SA, Barcelona has higher revenue and earnings than Mateon Therapeutics. Mateon Therapeutics is trading at a lower price-to-earnings ratio than Grifols SA, Barcelona, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Grifols SA, Barcelona has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.

Institutional & Insider Ownership

22.5% of Grifols SA, Barcelona shares are owned by institutional investors. 4.5% of Mateon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Grifols SA, Barcelona and Mateon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Grifols SA, Barcelona 13.16% 18.08% 6.22%
Mateon Therapeutics N/A -210.82% -175.67%

Analyst Ratings

This is a summary of current recommendations for Grifols SA, Barcelona and Mateon Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grifols SA, Barcelona 0 1 3 0 2.75
Mateon Therapeutics 0 1 3 0 2.75

Mateon Therapeutics has a consensus target price of $1.75, indicating a potential upside of 664.19%. Given Mateon Therapeutics’ higher possible upside, analysts clearly believe Mateon Therapeutics is more favorable than Grifols SA, Barcelona.

Dividends

Grifols SA, Barcelona pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%. Mateon Therapeutics does not pay a dividend. Grifols SA, Barcelona pays out 30.1% of its earnings in the form of a dividend.

Summary

Grifols SA, Barcelona beats Mateon Therapeutics on 8 of the 12 factors compared between the two stocks.

About Grifols SA, Barcelona

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

About Mateon Therapeutics

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply